Peel Therapeutics CEO Joshua Schiffman Presents at CureCRC Summit
December 18, 2025
Congrats to Peel’s CEO for his talk at Colorectal Cancer Alliance‘s 2025 CureCRC Summit. PEEL-224 offers a new approach to treating cancer with better efficacy and less toxicity. Our company looks forward to continuing to test PEEL-224 in patients on multiple clinical trials.
PEEL-224 offers a new way of treating aggressive cancers like metastatic CRC. PEEL-224 is a new cancer medicine with a delivery optimized, novel TOPO1 inhibitor payload showing early promise for patients. Excited to introduce a new way to treat cancer with better efficacy and less toxicity.
Recent News
- Canyon Labs Launches Expanded Reprocessing Validation Services for Medical Devices
- Connecting with Life Sciences in Logan
- Halia Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
- Ratio Therapeutics Enters into Research Collaboration, License Agreement with RayzeBio to Advance a Novel Radiopharmaceutical Program
- Co-Diagnostics Completes New Vector Smart® Laboratory Installations Amid Rising Dengue Activity in Florida
- Co-Diagnostics Launches Integrated Cloud and Mobile Infrastructure in India
